Matrigel 支架联合人胎盘间充质基质细胞改善小鼠切除创面组织学修复

Article
Open access
Published: 25 October 2026

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Impaired cutaneous wound healing remains a major clinical challenge, particularly when excessive inflammation disrupts tissue regeneration and extracellular matrix remodeling. Mesenchymal stromal cells (MSCs; the term recommended by the International Society for Cell & Gene Therapy in preference to “mesenchymal stem cells”) have been proposed as therapeutic agents on the basis of their immunomodulatory and paracrine properties. Human placenta-derived mesenchymal stromal cells (hPMSCs) are of particular interest because of their accessibility, proliferative capacity and low reported immunogenicity. Whether their benefit in cutaneous wounds is attributable to the cells themselves, to the delivery vehicle, or to both, has not been resolved. In this preclinical study, two full-thickness excisional wounds were created on the dorsum of female BALB/c mice and treated by intradermal injection with hPMSCs alone, hPMSCs incorporated within a Matrigel scaffold, Matrigel alone, or vehicle (DMEM) control. Separate cohorts were euthanized on days 7, 14 and 21 post-wounding (n = 5 mice, 10 wounds, per group per time point). Wound repair was assessed by histological and histomorphometric analysis of haematoxylin and eosin and Masson’s trichrome-stained sections. Collagen density was quantified morphometrically from Masson’s trichrome-stained sections, and re-epithelialization was graded on a five-point ordinal scale. Inflammatory cell infiltration and skin appendage regeneration were described qualitatively and were not quantified; inflammatory cells were not counted, and serial macroscopic wound-area measurements were not performed. Serum interleukin-10 (IL-10), interleukin-17 (IL-17) and interferon-γ (IFN-γ) were measured by ELISA on days 7, 14 and 21 as indices of the systemic inflammatory response. All three treatments improved histological repair relative to vehicle control. At day 21, collagen density was 86.1 ± 7.5% in the hPMSC + Matrigel group, compared with 77.8 ± 6.6% for Matrigel alone, 68.4 ± 5.1% for hPMSCs alone and 45.1 ± 4.1% for vehicle control. Across the three time points, the improvement in collagen density observed with Matrigel alone was 80–93% as large as the combination-versus-vehicle difference when the group means were compared descriptively. Adding hPMSCs to the scaffold gave a modest further increase of 5.8, 3.8 and 8.3% points at days 7, 14 and 21, which remained significant after Bonferroni adjustment only at day 7. The combination showed the highest re-epithelialization grade and the most organized dermal architecture on qualitative histological assessment at day 21. Systemically, hPMSC administration was associated with elevated serum IL-10 and reduced IFN-γ relative to control, with little difference in IL-17. In this model, a Matrigel scaffold improved histological wound repair relative to vehicle; adding hPMSCs to the scaffold gave a modest further increase in collagen density, and the combination performed best of the conditions tested. Because the study includes no non-MSC cellular control, the incremental benefit of the cells over the scaffold cannot be attributed specifically to hPMSC identity; and because no local (wound-bed) immunological or angiogenic analysis was performed, the accompanying serum cytokine changes represent a systemic association rather than a demonstrated local immunomodulatory mechanism. These findings should be regarded as an initial preclinical observation supporting combined cell–scaffold delivery, which requires confirmation with an appropriate cellular control and direct assessment of the wound microenvironment.

Funding

No financial support has been received from any organization.

Author information

Authors and Affiliations

Department of Molecular Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
Roya Saeedifar & Farzad Parvizpour
Universal Scientific Education and Research Network (USERN), Sanandaj, Kurdistan, Iran
Ramyar Rahimi Darehbagh
Health Metrics and Evaluation Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
Ramyar Rahimi Darehbagh
Research Center for War-Affected People, Tehran University of Medical Sciences, Tehran, Iran
Arefeh Jafarian
Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
Borhan Moradveisi
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
Farzad Parvizpour

Authors

Roya Saeedifar
Ramyar Rahimi Darehbagh
Arefeh Jafarian
Borhan Moradveisi
Farzad Parvizpour

Corresponding author

Correspondence to Farzad Parvizpour.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Iran National Committee for Ethics in Biomedical Research. Approval Code: IR.TUMS.VCR.REC.1397.955.

Declaration of generative AI in scientific writing

While preparing this work, the authors used “GPT-5.2” AI to check the grammar issues and make the text more narrative. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the publication’s content.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Cite this article

Saeedifar, R., Darehbagh, R.R., Jafarian, A. et al. Matrigel scaffold, alone or with human placenta-derived mesenchymal stromal cells, improves histological repair of murine excisional wounds. Sci Rep (2026). https://doi.org/10.1038/s41598-026-76889-9

Download citation

Received: 09 June 2026
Accepted: 15 October 2026
Published: 25 October 2026
DOI: https://doi.org/10.1038/s41598-026-76889-9